Funding Opportunity PAR-21-307 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with Alzheimers disease (AD) and Alzheimers disease-related dementias (ADRD) and of those providing their care.

Funding Opportunity PAR-21-308 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement(FOA) will support pragmatic trials within Stage IV of the NIH Stage Model to improve dementia care across multiple dementia care settings that will: (1) be designed to address practical comparative questions faced by Alzheimers disease (AD) and AD-related dementia (ADRD) patients, clinicians, and caregivers (both paid and unpaid); (2) include broad and diverse populations; and (3) be conducted in real-world settings with adequate sample size. These trials are intended to produce results that can be directly adopted by healthcare providers, patients, or caregivers for rapid dissemination and implementation. Successful applications will: (1) improve quality of care of persons with dementia; (2) improve quality of life for persons with dementia and their informal caregivers; (3) deliver more patient-focused, cost-effective care across multiple settings; and/or (4) reduce disparities in dementia care.

Funding Opportunity PAR-21-305 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.

Preference will be given to individuals with previous laboratory experience with cell biology techniques, high-resolution imaging, RNAseq analysis, and tissue…
From University of Wisconsin–Madison - Wed, 11 Aug 2021 00:58:05 GMT - View all Madison, WI jobs

Notice NOT-DK-21-025 from the NIH Guide for Grants and Contracts

Competitive dependent on skills and experience: Catherine Murphy: Reports to: Philippa Matthews, Group Leader This is a full-time, fixed term (12 months) position on Crick terms and conditions of employment, which... London (Greater) (GB)

GBP50000.00 - GBP60000.00 per annum: SRG: Laboratory Services Manager Cambridge, England

GBP45000.00 - GBP50000.00 per annum: SRG: Head of Training and Quality Cambridge, England

Funding Opportunity PAR-22-024 from the NIH Guide for Grants and Contracts. This FOA invites investigation of biological and clinical measures of TBI-related progressive neurodegeneration and neurocognitive decline associated with increased risk for dementia and /or traumatic encephalopathy syndrome (TES) (clinicopathologic diagnostic counterpart to the neuropathological diagnosis of Chronic Traumatic Encephalopathy (CTE)). Investigations should be based on existing, well-characterized populations of patients with a history of TBI that are enriched for increased risk of cognitive impairment or dementia and can continue to be followed longitudinally; additional subjects may be recruited as appropriate. The overall goal is to advance knowledge of the underlying pathophysiology and clinical characterization of the chronic effects of TBI that distinguish static-chronic TBI cognitive impairment from those that lead to progressive neurodegeneration associated with TES and dementia. A critical feature of this FOA includes the broad sharing of clinical, neuroimaging, physiological, and biospecimen data and to create a data and associated biofluid resource for the broader community to further advance research in this area.

Bioinformatics approaches for analysis of data sets. Experience with molecular methods including nucleic acid extraction, purification, PCR design and next…
From University of Wisconsin–Madison - Tue, 10 Aug 2021 00:58:12 GMT - View all Madison, WI jobs

In this installment of Your Unicorn Career, our columnist advises about guarding your career against attacks from within

GBP39748.0 - GBP44166.0 per annum: Science and Technology Facilities Council (STFC): HNCDI Computational Biologist/Bioinformatician £39,748 - £44,166 Gross per AnnumScience and Technology Facilities Council (STFC), UKRIDo you pride yo Warrington, England

Funding Opportunity RFA-MD-21-003 from the NIH Guide for Grants and Contracts. This initiative will support a single resource center to provide focused technical assistance and support to Tribal Epidemiology Centers (TECs) to enhance the research and data science capacity for health research focused on American Indian/Alaska Native (AI/AN) populations.

Notice NOT-OD-21-172 from the NIH Guide for Grants and Contracts

£32,780-£41,093: Wellcome Sanger Institute: The Opportunity: The Bentley team is seeking an enthusiastic and self-motivated Postdoctoral Fellow to contribute to the group’s pathogen genomics ... Cambridge, Cambridgeshire (GB)

Funding Opportunity PAR-22-023 from the NIH Guide for Grants and Contracts. Recent findings have raised the hypothesis that systemic immune responses could play direct or indirect roles in brain neurodegeneration leading to AD/ADRD, and has been significantly less studied compared to innate immune mechanisms such as microglia in the brain. This initiative will capitalize on growing interest in the research community and will support partnerships and new collaborations between neuroscientists and immunologists to expand the research base in this area with the long-term goal of bringing more immunology expertise into the AD/ADRD field. This is a new initiative seeking research into the role of systemic immune responses and inflammation in AD/ADRD. Individual projects are sought and collaborations between neuroscientists with expertise in AD/ADRDs and immunologists will be highly encouraged. Through these awards, a more solid research base in this area will be established that can support further work in this area through investigator-initiated and other mechanisms.

Funding Opportunity RFA-HG-21-029 from the NIH Guide for Grants and Contracts. This FOA is one of three issued to create a new program called "Molecular Phenotypes of Null Alleles in Cells (MorPhiC)". The long-term goal of MorPhiC is to develop a consistent catalog of molecular and cellular phenotypes for null alleles for every human gene, using in vitro multicellular systems. The catalog will be made available for broad use by the biomedical community. The program will start with a Phase 1 to optimize available methods to create null alleles and measure their phenotypic effects in a target subset of 1000 protein coding genes across the program. Phase I will also assess the scale limitations of such methods, develop common data formats, and establish use cases for this catalog. This specific FOA seeks applications for MorPhiC Data Production Research and Development Centers, which will develop diverse systems and assays and explore and compare approaches to produce MorPhiC data at scale, and to maximize its informativeness.

Funding Opportunity RFA-HG-21-031 from the NIH Guide for Grants and Contracts. This FOA is one of three issued to create a new program called "Molecular Phenotypes of Null Alleles in Cells (MorPhiC)". The long-term goal of MorPhiC is to develop a consistent catalog of molecular and cellular phenotypes for null alleles for every human gene, using in vitro multicellular systems. The catalog will be made available for broad use by the biomedical community. The program will start with a Phase 1 to optimize available methods to create null alleles and measure their phenotypic effects in a target subset of 1000 protein coding genes across the program. Phase I will also assess the scale limitations of such methods, develop common data formats, and establish use cases for this catalog. This specific FOA seeks applications for MorPhiC Data Analysis and Validation Centers. These Centers will develop computational models and data analysis and visualization methods to evaluate and help ensure the utility of the MorPhiC data. Separate FOAs will be issued for the two other components of MorPhiC: Data Production Research and Development Centers and a Data Resource and Administrative Coordination Center to receive, annotate, and present data for consortium and public use and to be the administrative coordinating center for the MorPhiC consortium.

Funding Opportunity RFA-HG-21-030 from the NIH Guide for Grants and Contracts. This FOA is one of three issued to create a new program called "Molecular Phenotypes of Null Alleles in Cells (MorPhiC)". The long-term goal of MorPhiC is to develop a consistent catalog of molecular and cellular phenotypes for null alleles for every human gene, using in vitro multicellular systems. The catalog will be made available for broad use by the biomedical community. The program will start with a Phase 1 to optimize available methods to create null alleles and measure their phenotypic effects in a target subset of 1000 protein coding genes across the program. Phase I will also assess the scale limitations of such methods, develop common data formats, and establish use cases for this catalog. This specific FOA seeks applications for MorPhiC Data Analysis and Validation Centers. These Centers will develop computational models and data analysis and visualization methods to evaluate and help ensure the utility of the MorPhiC data. Separate FOAs will be issued for the two other components of MorPhiC: Data Production Research and Development Centers and a Data Resource and Administrative Coordination Center to receive, annotate, and present data for consortium and public use and to be the administrative coordinating center for the MorPhiC consortium.

Funding Opportunity RFA-NS-22-001 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support hypothesis-driven clinical research applications that are focused on discovering novel diagnostic, prognostic, and/or therapeutic biomarkers for the Lewy Body Dementias (LBD).Biomarker research must be conducted in patients with LBD, must follow Parkinson's Disease Biomarker Program (PDBP) protocols for clinical assessment and biospecimen collection,and must be broadly shareable through the PDBP repositories.